Mark DeSaulnier

Responsible Retirement of Law Enforcement Firearms Act of 2025 or the RRLEF Act of 2025

This bill establishes a framework to limit the transfer of firearms to and purchase from federally licensed gun dealers whose firearms have a short time to crime. The term short time to crime means a period of three years or less between the date of the last known retail sale of a firearm and the date a firearm is recovered in an actual or suspected criminal offense.

Specifically, the bill directs the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) to notify a state or local law enforcement agency if a firearm transferred by the agency is used, or suspected of being used, in the commission of a criminal offense, as traced by the National Tracing Center.

Additionally, the bill directs the ATF to publish annually a list of federally licensed gun dealers who have 25 or more traces of firearms with a short time to crime in at least two of the three previous years.

The bill prohibits a state (including the District of Columbia), territory, or local government that receives funds under the Edward Byrne Memorial Justice Assistance Grant Program from transferring a firearm to, or purchasing a firearm from, a dealer on the list.

The bill removes limits on the authority of the ATF to disclose firearms tracing data.

Sickle Cell Disease Comprehensive Care Act

This bill allows state Medicaid programs to establish health homes to provide coordinated care for individuals with sickle-cell disease. (Under current law, state Medicaid programs may establish health homes to provide coordinated care for individuals with specified chronic conditions.) States must ensure that such care includes dental and vision services.

The Centers for Medicare & Medicaid Services must issue best practices for states on how to design and implement such health homes.

Improving Menopause Care for Veterans Act of 2025

This bill requires the Government Accountability Office (GAO) to study and report on the medical services furnished by the Department of Veterans Affairs (VA) for veterans experiencing perimenopause, genitourinary syndrome of menopause, and menopause stages. The VA must also report to Congress on a strategic plan to (1) implement any recommendations GAO makes in its report, (2) improve the quality of menopause care, and (3) improve the access of veterans to menopause care.

Infant Formula Safety Modernization Act of 2026

This bill directs the Food and Drug Administration (FDA) to expand requirements for the testing of infant formula and formula manufacturing facilities for pathogens and microorganisms.

Current regulations generally require manufacturers to test finished formula products for Cronobacter and Salmonella. The FDA tests manufacturing facilities for these contaminants in regular inspections, but manufacturers are not required to test their own facilities.

Within 90 days of the bill's enactment, the FDA must issue a final rule requiring manufacturers to test their facilities and finished formula products for certain pathogens and microorganisms, including Clostridium botulinum (which causes botulism). These regulations must include a recommended frequency for facilities testing, including requirements for testing different areas based on their proximity to formula products.

Manufacturers must notify the FDA within one business day of any positive result for one of the specified pathogens or microorganisms in a finished formula product, even if the product is still in the manufacturer’s possession. (Currently, notice is required only if the affected product has left the manufacturer’s facilities.) Manufacturers must also retain records of any positive result (from a test of formula or facilities).

The FDA must notify Congress within one business day of

• receiving notice of a positive test result for a finished formula product, or

• recommending official corrective action to address the findings of a facility inspection.

Finally, the regulations must explicitly require the FDA to enforce consistent inspection and compliance standards for all formula products, including imported products.

Supplemental Oxygen Access Reform Act of 2025 or the SOAR Act of 2025

This bill establishes certain requirements with respect to the payment and provision of supplemental oxygen and related services under Medicare.

For example, the bill provides for separate payments, indexed to inflation, of oxygen and related equipment, supplies, and services under Medicare (rather than under the competitive acquisition program). It also specifically covers services that are provided by respiratory therapists under Medicare and provides for an additional payment adjustment for these services.

Additionally, the bill (1) requires the Centers for Medicare & Medicaid Services to develop an electronic template for providers to use when prescribing oxygen and related equipment, supplies, and services; and (2) establishes certain rights for beneficiaries receiving these items and services, such as the right to choose their suppliers and to receive clear communications and be informed about the services provided.

Alzheimer's Screening and Prevention Act of 2025 or the ASAP Act

This bill provides for Medicare coverage of blood tests to screen for the early stages of Alzheimer’s disease or related dementias. Specifically, the bill provides for coverage of genomic sequencing blood or blood product tests, or other equivalent tests, that are approved by the Food and Drug Administration.

North Platte Canteen Congressional Gold Medal Act

This bill provides for the award of a Congressional Gold Medal to recognize the individuals and communities that provided financial and other support for the North Platte Canteen in North Platte, Nebraska, during World War II.

This resolution expresses support for the designation of National Hispanic-Serving Institutions Week.